SUNPHARMA.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:00):

Stats
Tagesvolumen	1.79M
Durchschnittsvolumen	2.82M
Marktkapitalisierung	3 614.64B
EPS	INR10.50 ( 2024-01-31 )
Nächstes Ertragsdatum	( INR6.83 ) 2024-05-24
Last Dividend	INR4.00 ( 2023-07-28 )
Next Dividend	INR0 ( N/A )
P/E	40.62
ATR14	INR1.647 (0.11%)

Volumen Korrelation

Lang: 0.42 (neutral)

Kurz: 0.84 (strong)

Signal:(63.749) Same movement expected

Sun Pharmaceutical Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Sun Pharmaceutical Korrelation - Währung/Rohstoff

0.42
( neutral )

0.27
( neutral )

-0.57
( weak negative )

0.42
( neutral )

-0.15
( neutral )

0.25
( neutral )

Sun Pharmaceutical Finanzdaten

Annual	2022
Umsatz:	INR432.79B
Bruttogewinn:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Umsatz:	INR432.79B
Bruttogewinn:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Umsatz:	INR384.26B
Bruttogewinn:	INR267.19B (69.53 %)
EPS:	INR13.60

FY	2021
Umsatz:	INR334.98B
Bruttogewinn:	INR236.13B (70.49 %)
EPS:	INR12.10

Financial Reports:

No articles found.

Sun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.00 (N/A)	INR0 (N/A)	INR7.50 (N/A)	INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Sun Pharmaceutical Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.54 - low (17.82%) | Divividend Growth Potential Score: 4.46 - Stable (10.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0208	1996-06-24
Last Dividend	INR4.00	2023-07-28
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR59.60	--
Avg. Dividend % Per Year	0.77%	--
Score	2.84	--
Div. Sustainability Score	3.54
Div.Growth Potential Score	4.46
Div. Directional Score	4.00	--

Next Divdend (Est)
(2024-06-03)

INR4.08 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.39%
2019	INR2.75	0.63%
2020	INR4.00	0.92%
2021	INR7.50	1.26%
2022	INR10.00	1.18%
2023	INR11.50	1.15%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SRF.NS	Dividend Junior	2023-08-01	Semi-Annually	21	0.25%
MRF.NS	Dividend Knight	2023-07-20	Semi-Annually	23	0.11%
HGINFRA.NS	Dividend Junior	2023-08-14	Sporadic	7	0.13%
BLISSGVS.NS	Dividend Junior	2023-07-12	Annually	15	0.46%
RBLBANK.NS	Dividend Junior	2023-08-18	Sporadic	8	0.25%
KOVAI.NS	Dividend Junior	2023-08-10	Annually	4	0.17%
EXIDEIND.NS	Dividend Junior	2023-08-01	Annually	22	0.76%
AMIORG.NS	Dividend Junior	2023-09-18	Annually	3	0.15%
TALBROAUTO.NS	Dividend Junior	2023-09-15	Annually	18	0.48%
NGIL.NS	No Dividend Player	2023-09-21	Annually	4	0.08%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.191	1.500	6.18	9.28	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	43.19	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
freeCashFlowPerShareTTM	21.49	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.774	1.000	0.428	0.428	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.23	7.23	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	40.59	1.000	6.00	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	21.49	2.00	2.84	10.00	[0 - 30]
dividendYielPercentageTTM	0.830	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.255	1.500	-1.631	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.110	1.000	9.74	0	[0.1 - 0.5]
Total Score				4.46

Sun Pharmaceutical

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.